Algert Global LLC Increases Position in Inari Medical, Inc. (NASDAQ:NARI)

Algert Global LLC boosted its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 38.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,106 shares of the company's stock after purchasing an additional 12,180 shares during the period. Algert Global LLC owned approximately 0.08% of Inari Medical worth $1,819,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. increased its stake in Inari Medical by 11.1% in the 1st quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company's stock worth $268,681,000 after buying an additional 561,562 shares during the period. Jennison Associates LLC grew its stake in Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock worth $65,021,000 after acquiring an additional 610,468 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company's stock worth $71,324,000 after acquiring an additional 786,691 shares during the period. Armistice Capital LLC raised its stake in shares of Inari Medical by 353.1% during the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company's stock valued at $48,595,000 after acquiring an additional 786,501 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Inari Medical by 26.8% during the second quarter. American Century Companies Inc. now owns 980,917 shares of the company's stock valued at $47,231,000 after acquiring an additional 207,485 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company's stock.

Inari Medical Stock Up 0.4 %

Shares of Inari Medical stock traded up $0.20 during trading on Thursday, reaching $51.03. The company's stock had a trading volume of 532,896 shares, compared to its average volume of 983,324. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $67.13. The company has a 50-day simple moving average of $46.00 and a two-hundred day simple moving average of $47.45. The company has a market cap of $2.99 billion, a price-to-earnings ratio of -37.80 and a beta of 0.96.

Analysts Set New Price Targets

Several research analysts have commented on the company. Robert W. Baird raised their price objective on Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a report on Tuesday, October 29th. Wells Fargo & Company lowered their price objective on shares of Inari Medical from $84.00 to $65.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Inari Medical in a research report on Friday, August 9th. They set a "buy" rating and a $68.00 target price on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Inari Medical in a research report on Tuesday, October 29th. Finally, Truist Financial increased their price objective on shares of Inari Medical from $46.00 to $50.00 and gave the company a "hold" rating in a research note on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Inari Medical has a consensus rating of "Hold" and an average target price of $58.89.

Insider Transactions at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now owns 445,310 shares in the company, valued at approximately $22,265,500. This represents a 0.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William Hoffman sold 60,000 shares of Inari Medical stock in a transaction on Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the sale, the director now owns 501,233 shares of the company's stock, valued at $25,643,080.28. The trade was a 10.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 186,000 shares of company stock worth $8,990,990. Insiders own 10.60% of the company's stock.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.